Product Program year 2025 Source: CMS Open Payments

Protonix

Drug Gastrointestinal

NDC 0008-0844-02

Open in the dashboard

General payments

$28,079

19 payments

Research payments

$731,082

168 payments

Through program year 2025, $28,079 in general payments and $731,082 in research payments were reported against Protonix (Gastrointestinal).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $4,250 1
2025 Research $62,146 21
2024 General $14,000 3
2024 Research $98,552 30
2023 General $7,750 1
2023 Research $153,335 36
2022 Research $167,155 18
2021 Research $64,091 16
2020 Research $82,776 18
2019 General $2,079 14
2019 Research $103,028 29

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $28,079 19 payments
Top recipients General payments · program year 2025
  1. Benjamin Gold Pediatric Gastroenterology · Atlanta, GA $4,250 100% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Pediatric Gastroenterology Pediatrics $4,250 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Georgia $4,250 100% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

3,239

Prescriptions dispensed, refills included

Drug cost

$1,477,275

Paid at the pharmacy, in all

Medicare Part D drugs matched to PROTONIX, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Protonix Pantoprazole Sodium Same name 164 2,979 $1,451,348
Protonix Iv Pantoprazole Sodium Similar name 8 260 $25,927

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 108 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sanju Baino Nurse Practitioner TX 88 $11,104 No profile
Michael Calnicean Physician Assistant MI 76 $19,124 None on record
Ashraf Mostafa Internal Medicine MD 65 $13,271 None on record
Vanessa Kinney Nurse Practitioner SC 63 $84,512 None on record
Raj Rao General Practice MI 61 $16,382 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 108 with Patron
19 general · 168 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record